Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment
Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment. // Journal of Cystic Fibrosis. – URL: https://www.sciencedirect.com/science/article/pii/S1569199326016383?dgcid=rss_sd_all
Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment. Journal of Cystic Fibrosis. https://www.sciencedirect.com/science/article/pii/S1569199326016383?dgcid=rss_sd_all
“Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment.” Journal of Cystic Fibrosis.
@article{article53051,
title = {Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment},
journal = {Journal of Cystic Fibrosis},
url = {https://www.sciencedirect.com/science/article/pii/S1569199326016383?dgcid=rss_sd_all}
}
ABSTRACT Aim To investigate the longitudinal association between early‐life movement behaviour patterns and later clinically diagnosed obesity. Method In the population‐based All Babies in Southeast Sweden (ABIS) cohort, 16 415 children...